## Shereif H Rezkalla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7608179/publications.pdf

Version: 2024-02-01

27 papers 1,672 citations

15 h-index 642732 23 g-index

27 all docs

27 docs citations

27 times ranked

2218 citing authors

#	Article	IF	Citations
1	No-Reflow Phenomenon. Circulation, 2002, 105, 656-662.	1.6	530
2	Coronary noâ€reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheterization and Cardiovascular Interventions, 2008, 72, 950-957.	1.7	192
3	Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC: Cardiovascular Interventions, 2017, 10, 215-223.	2.9	160
4	The Role of Aspirin in the Prevention of Cardiovascular Disease. Clinical Medicine and Research, 2014, 12, 147-154.	0.8	146
5	Noâ€Reflow Phenomenon Following Percutaneous Coronary Intervention for Acute Myocardial Infarction: Incidence, Outcome, and Effect of Pharmacologic Therapy. Journal of Interventional Cardiology, 2010, 23, 429-436.	1.2	124
6	Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Annals of Emergency Medicine, 2003, 42, 365-369.	0.6	101
7	Cardiovascular consequences of cocaine use. Trends in Cardiovascular Medicine, 2015, 25, 517-526.	4.9	74
8	Ischemic preconditioning and preinfarction angina in the clinical arena. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 96-102.	3.3	72
9	Cocaine-Induced Acute Myocardial Infarction. Clinical Medicine and Research, 2007, 5, 172-176.	0.8	65
10	Viral myocarditis: 1917–2020: From the Influenza A to the COVID-19 pandemics. Trends in Cardiovascular Medicine, 2021, 31, 163-169.	4.9	46
11	Preconditioning in humans. Heart Failure Reviews, 2007, 12, 201-206.	3.9	38
12	Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheterization and Cardiovascular Interventions, 2003, 58, 76-79.	1.7	31
13	Influenza-related viral myocarditis. Wisconsin Medical Journal, 2010, 109, 209-13.	0.3	21
14	Coronary no-reflow phenomenon. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 75-80.	0.9	18
15	Aspirin overutilization for the primary prevention of cardiovascular disease. Clinical Epidemiology, 2014, 6, 433.	3.0	18
16	Aspirin in Primary Prevention of Cardiovascular Events. Clinical Medicine and Research, 2020, 18, 89-94.	0.8	10
17	Antiplatelet Therapy from Clinical Trials to Clinical Practice. Clinical Medicine and Research, 2003, $1$ , $101-104$ .	0.8	9
18	Contrast Nephropathy. Clinical Medicine and Research, 2003, 1, 301-304.	0.8	5

#	Article	IF	CITATIONS
19	Myocardial infarction temporally related to ephedra—a possible role for the coronary microcirculation. Wisconsin Medical Journal, 2002, 101, 64-6.	0.3	4
20	Successful Direct Stenting Guided by Intravascular Ultrasound without Contrast in a Patient with Renal Dysfunction. Journal of Interventional Cardiology, 2003, 16, 449-451.	1.2	3
21	Post-Acute Sequelae of SARS-COVID-2 Syndrome: Just the Beginning. Cardiology Research, 2021, 12, 279-285.	1.1	3
22	Lipid-Rich Plaque Masquerading as a Coronary Thrombus. Clinical Medicine and Research, 2006, 4, 119-122.	0.8	1
23	Effectiveness of acetylcysteine on preventing renal dysfunction in patients undergoing coronary procedures. Wisconsin Medical Journal, 2004, 103, 38-41.	0.3	1
24	Author Response to "Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas― Clinical Medicine and Research, 2021, 19, 1.2-2.	0.8	0
25	Ischemic preconditioning for the clinician. Wisconsin Medical Journal, 2006, 105, 22-6.	0.3	0
26	Management strategies for ST-elevation myocardial infarction in the emergency department. Wisconsin Medical Journal, 2007, 106, 219-24.	0.3	0
27	ST Segment Elevation Myocardial Infarction in the COVID-19 Era: Appraisal of the Evidence. Clinical Medicine and Research, 2022, 20, 52-60.	0.8	0